None listed
Conditions
Interventions
Intervention1: Olepent® cream: 1 FTU application twice a day (morning and night)on full face up to eight weeks.
Control Intervention1: Placebo: 1 FTU application twice a day (morning and night)on ful
Sponsors
Sami Labs Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1 Female adult subjects in general good health as determined from a recent medical history general physical examination, dermatological assessment. 2 Subjects in the age group of 35-50 years (both ages inclusive). 3 Subject with Fitzpatrick skin types III to V. 4 Subjects having visible fine lines and wrinkles in periorbital area (Crows feet under eye) and forehead 5 Subject free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face. 6 Subject who agrees not to use any other product/treatment/home remedy except the provided dove soap bar on their face during the study period other than the test product. 7 Subjects who agree not to carry out bleaching or any other procedures including facial etc. on face during the study period. 8 Subjects who agree not to expose to excessive sun light. (Sun exposure not more than half an hour daily and during that time use of umbrella to cover face). 9 Subjects willing to give a voluntary written informed consent, photography release and agree to come for regular follow up. 10 Subjects willing to abide by and comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1 Subject with any other signs of significant local irritation or skin disease. 2 Subject currently taking any medication, which the Investigator believes may influence the interpretation of the data. 3 Subject having clinically significant systemic or cutaneous disease, chronic illness or had major surgery in the last year. 4 Subjects who do not agree to remove all jewellery on/around face (e.g. necklace,earrings,if possible nose ring),during VISIA imaging. 5 Subjects having hairstyle which covers almost the entire forehead. 6 Subjects undergoing any treatment of any skin condition on their face/forearm. 7 Subjects not willing to discontinue other topical facial products. 8 Subject allergic or sensitive to bar cleansing products, cosmetics, creams/lotions, artificial jewellery or anything else. 9 Pregnant women (as confirmed by UPT) and lactating women. 10 Subjects on any medical treatment either systemic/topical in the past 1 month or currently taking medication including food supplements. 11 Subjects with skin allergy history or atopic dermatitis or psoriasis 12 Subjects who have participated in any other clinical trial in the last 3 months. 13 Subjects using oral contraceptive pills or hormonal implants as birth control measures during the study 14 Subjects that was treated with botox/filler /biostimulatory molecules injection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 Mean reduction in facial fine line, wrinkles and elasticity as assessed by Antera & Dermatological visual assessmentTimepoint: 1 Mean reduction in facial fine line, wrinkles and elasticity as assessed by Antera & Dermatological visual assessment (Screening, Baseline, Day 28 and Day 56) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Mean reduction in facial fine line; wrinkles and elasticity - VISIA CR; Cutometer 2 Mean change in skin quality as assessed by Skin texture, firmness & elasticity scale (In use scales); validated Crows feet grading scale & by Self assessment. 3 Mean increase in skin hydration - Corneometer. 4 Evaluation of safety through monitoring skin tolerance & AE.Timepoint: 1 Mean reduction in facial fine line;wrinkles and elasticity - VISIA CR,Cutometer (Screening, Baseline,Day28 & Day56) 2 Mean change in skin quality as assessed by Skin texture, firmness & elasticity scale (In use scales); validated Crows feet grading scale & by Self-assessment (Screening, Baseline,Day28 & Day56). 3 Mean increase in skin hydration - Corneometer (Screening, Baseline,Day28 & Day56). 4 Evaluation of safety through monitoring skin tolerance & AE (Baseline, Day28 & Day56). | — |
Countries
India
Contacts
Public ContactDr Kalpesh Shah
ClinWorld Private Limited
Outcome results
None listed